Humana Inc. (NYSE:HUM) Receives $285.68 Average Price Target from Brokerages

Humana Inc. (NYSE:HUM) has been given a consensus recommendation of “Hold” by the twenty-two analysts that are presently covering the firm, MarketBeat.com reports. Seventeen investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $285.68.

A number of equities analysts recently weighed in on the stock. Truist Financial lifted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays lifted their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Finally, Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th.

Humana Trading Down 0.2 %

Shares of HUM stock opened at $266.33 on Friday. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $32.14 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 2.05 and a beta of 0.57. The stock has a 50-day moving average of $271.33 and a 200-day moving average of $276.25.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities research analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.37% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dodge & Cox increased its stake in Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares in the last quarter. Norges Bank purchased a new stake in shares of Humana during the fourth quarter valued at approximately $416,202,000. Pzena Investment Management LLC lifted its holdings in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after acquiring an additional 1,103,132 shares during the period. Finally, Boston Partners boosted its position in Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after purchasing an additional 893,637 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.